The Food and Drug Administration's actions on ephedra and androstenedione: understanding their potential impacts on the protections of the Dietary Supplement Health and Education Act.
Siegner
A Wes
AW
Hyman, Phelps & McNamara, P.C., Washington, D.C., USA.
D000735:Androstenedione / Q000592:standards / Q000627:therapeutic use*; D003257:Consumer Product Safety / Q000331:legislation & jurisprudence*; D003362:Cost-Benefit Analysis; D019587:Dietary Supplements / Q000266:history / Q000592:standards; D029789:Ephedra; D049673:History, 20th Century; D006801:Humans; D031665:Oenothera biennis; D008517:Phytotherapy; D028321:Plant Preparations / Q000494:pharmacology / Q000627:therapeutic use; D010946:Plants, Medicinal; D011356:Product Labeling / Q000331:legislation & jurisprudence; D014481:United States; D014486:United States Food and Drug Administration
D028321:Plant Preparations; D000735:Androstenedione